CTLA4 and cancer: Immunotherapy aims at reactivating repressive immune cells of cancer patients and acquires exciting results, especially for immune checkpoint blockers of immune monoclonal antibodies, such as PD-1 antibody, PD-L1 antibody, as well as CTLA-4 antibody (Carbone et al., 2017).